Serenity Tree

Rest in Peace, Janis Timma. The news of Janis’ passing at just 32 years old serves as a stark reminder of the silent struggles so many face. While his presence on the court was celebrated, we often don’t see the battles happening off it. Suicide doesn’t discriminate—it affects people in all walks of life, including athletes who may appear strong and resilient. If you or someone you know is struggling, please know that help is available. You are not alone. Reach out. Speak up. 📞 Call the Suicide & Crisis Lifeline at 988 for immediate support in the U.S. 🖤 Check in on your loved ones, and don’t be afraid to ask for help. Mental health matters. Let’s work together to create a world where seeking support is seen as courage, not weakness.

Congratulations to Natalie Kohlhaas on the incredible achievement of her book reaching the semi-finalist level in the prestigious Chartier Awards! This recognition highlights her insightful exploration of anxiety and the profound impact her writing has had on readers. Well done, Natalie! 🎉📚 #ChartierAwards #Congratulations #HelloAnxietyMyOldFriend

At NAMI, we embrace the voices of lived experience while using numbers to illustrate the broader impact of mental health conditions on individuals, families, and communities. It's important to remember that every number represents unique stories from people navigating their mental health journeys. Whether you are a person with lived experience who wants to see yourself in the data, a student researching mental health conditions, or just someone who wants to learn more, NAMI’s Mental Health By The Numbers is here to help: nami.org/mhstats.

We are excited to announce a research collaboration agreement with Compass Pathways to inform the development of a scalable delivery and training model for COMP360 psilocybin treatment. Together, Compass and Journey Clinical will work to better understand the patient care experience, depression patient pathways, and care reimbursement processes, and explore innovative care pathways for treatment-resistant depression (TRD) patients, should COMP360 psilocybin treatment be approved. TRD is a form of depression that does not respond to conventional treatments and is estimated to affect 2.8 million people in the US. Treatments like Psychedelic-Assisted Psychotherapy, specifically psilocybin treatment, have the potential to make a big impact. Together, we will conduct research into therapist training, support, and education, and exchange information on treatment settings for psychedelic therapies. Journey Clinical Co-Founder and CEO Jonathan Sabbagh commented: “We are thrilled to be a research collaboration partner for Compass and to contribute towards how COMP360 psilocybin treatment may be delivered to patients across the US if it receives regulatory approval. [It] is closely aligned with Journey Clinical’s aim to support the millions of people in the US living with mental illness to access psychedelic treatments safely and effectively.” Kabir Nath, CEO of Compass Pathways, commented: “Compass is forming a comprehensive and diverse network of research collaborations to inform how COMP360 psilocybin treatment can be best integrated into the US health system. As a leader in bringing psychedelic treatments to patients in the US safely, responsibly, and at scale, Journey Clinical will be a valuable collaboration partner for Compass. Together, we will further refine our understanding of how COMP360 psilocybin treatment could be delivered to patients in the future.” Read the full press release on our website:  https://lnkd.in/gP3u5WvV